OnlyFans' reclusive billionaire owner Leo Radvinsky in talks to sell site
Leo Radvinsky, the sole owner of OnlyFans' London-based parent company Fenix International, was recently engaged in talks with an investor group led by the Forest Road Company, a Los Angeles-based investment firm, about a possible sale.
But the status of those talks is unclear and it appears that Radvinsky has engaged another unnamed entity that is considered a more promising bidder, according to the Wall Street Journal.
Last month, The Post reported that Radvinsky quietly put OnlyFans up for sale but that it was struggling to find a buyer due to its risque business model.
News that Radvinsky is shopping OnlyFans comes after it was revealed that he collected nearly $US1.3 billion ($A2bn) in dividends between 2019 and early 2024, according to British corporate filings.
Still, the mogul's ambition appears far from fulfilled. People familiar with the matter told the Journal that Radvinsky has recently engaged banks and suitors, sounding out a sale of OnlyFans for as much as $US8 billion.
The Post has sought comment from Radvinsky, OnlyFans and Forest Road Company.
While OnlyFans has become a cultural lightning rod and financial juggernaut — thanks largely to its explicit content and creator-led model — its owner remains almost entirely invisible.
At 43, Radvinsky has never given a public interview, rarely appears at industry events and has left behind only a single widely circulated image online. Even those who've worked with him are bound by strict nondisclosure agreements.
His official website describes him modestly as a company builder, an angel investor and an aspiring helicopter pilot.
There's no mention of OnlyFans — despite the fact that the site is the primary source of his estimated $US4bn ($A6.1bn) fortune.
A sale of OnlyFans at an $US8 billion valuation would further cement Radvinsky's place among the world's richest and most private tech entrepreneurs — and likely supercharge his philanthropic ambitions, according to the Journal.
Despite its adult content roots, OnlyFans has tried to rebrand itself as a mainstream content platform.
CEO Keily Blair, a former privacy lawyer, has stressed the site's diversity — highlighting comedy, sports, and music alongside more explicit fare.
The price tag, while high, might actually be a bargain.
OnlyFans is immensely profitable — something many fast-growing tech firms can't claim.
But the very thing that makes it so lucrative could also be what keeps potential acquirers at bay.
Even if a sale never materialises, Radvinsky doesn't seem pressed for cash.
He and Chudnovsky relocated to Florida, where they now reside in a palatial duplex once owned by tennis great Chris Evert, purchased for over $20 million.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
5 hours ago
- News.com.au
Airwrap Co-anda 2x: Dyson unveils $999 hair styling tool
EXCLUSIVE As Londoners swelter during an 'extreme' heatwave, I've taken refuge in a swanky hotel room overlooking the city's famous skyscrapers. But I'm not here to eyeball landmarks from the comfort of AC, something far hotter has lured me the almost 17,000kms from the office in Sydney to the UK's capital: Dyson's latest beauty launch. The British tech giant, best known for changing the way we all vacuum our homes, has fast become one of the world's most sought-after beauty brand's in recent years after launching the Dyson Supersonic hair dryer in 2016. Two years later, the engineering giants released the Airwrap, a 'game-changing' device that revolutionised the haircare industry with its ability to curl, wave, smooth, and dry hair without the use of extreme heat. Since then, the Airwrap – which some critics speculated would never take off – has arguably overtaken as Dyson's most popular product. You only have to take a quick glance on TikTok where the hashtag '#DysonAirwrap' has tens of millions of views to know the naysayers were very wrong. Today, the gadget is so integral to Dyson's beauty offering, the brand has just announced a new iteration that has twice the power to deliver even better results. The new 'supercharged' version of the cult hair tool, dubbed the Airwrap Co-anda 2x, is a 'next level multi-styler and hair dryer', Dyson says. So what makes it so special? flew all the way to London to be the first in Australia to test out the 6-in-1 hair styler – so here's everything you need to know. Extra oomph The Airwrap 2x comes with an improved Hyperdymium motor that has been 're-engineered from the ground up' to be what Dyson calls its 'fastest and most powerful hair care motor'. 'Dyson has developed a new motor for our Airwrap 2x, which spins at 150,000rpm, delivering twice the air pressure, faster drying, and less heat damage,' James Dyson, Founder and Chief Engineer, said. 'The high pressure creates a longer lasting curl and straighter styles. Traditional stylers can damage hair, but we have always focused on developing tools that protect hair health whilst enhancing without compromising precision or performance.' Described by the brand as 'the heart of the machine', the wire powering the motor is as thin as a strand of human hair, allowing Dyson to 'miniaturise' the device, enabling it to sit comfortably in the palm of your hand'. It's one of the key reasons the Airwrap 2x is smaller and lighter than its predecessors, the original Dyson Airwrap released in 2018 and later revamped in 2022, and the more recent Dyson Airwrap i.d launched in August last year. But despite producing more air pressure than ever, the 'supercharged' machine won't hurt your eardrums according to Dyson, who said its increased output hasn't affected the amount of noise it makes. Doing the hard work for you Clever AI-driven sensors have also been added to the Airwrap2x's attachments, to help 'take the guesswork' out of styling and maintenance of the machine. There are six attachments included that dry, curl, wave, straighten, smooth, and volumise hair that all contain an RFID chip that communicates with the machine to instantly adapt to the best temperature and airflow settings. The attachments are preset with recommended airflow and heat settings, but are customisable by the user on the MyDyson app. The once clunky experience of curling hair, which involves manipulating strands on the barrel attachment before blasting it with cool air, has been simplified with 'the i.d sequence' – an automatic four step process for 'consistent curls with a push of the action button'. Dyson introduced this last year with as a new feature on the Airwrap i.d following widespread complaints from users that the curling attachments were difficult to use. But now Dyson said the device produces the 'perfect curl every time'. There's even a new sensor that will let users know when the device's filter needs cleaning – talk about impressive. All new and improved attachments While many of the six attachments will feel familiar to loyal Airwrap users, there is one that is entirely new, and has been described by some as a mini-version of Dyson's wet-to-dry straightening device, the AirStrait. The AirSmooth 2x is a finishing attachment that can be used to smooth and straighten smaller sections of hair, such as bangs or baby hairs, without the need for hot ceramic plates. More recognisable attachments have also had a makeover, such as the paddle brush, which now has a swanky new name: the Anti-snag loop brush 2x. It features noticeably different bristles that are hooked for more control while styling, especially at roots and ends, and are softer on the scalp too to help prevent irritation. The Round volumising brush also comes in a new 2x edition, featuring improved bristles for more control. While the 20mm, 30mm and 40mm Co-anda 2x curling barrels have been tweaked too, with angular, square-shaped tips that are 'more ergonomic' compared to the original rounded ones for an easier grip. The booming beauty industry The supercharged motor has also enabled Dyson to give its hair drying attachment more bang for your buck than ever, delivering twice the air pressure to dry hair as fast as a full performance hair dryer. Now that's impressive – especially as it could potentially eliminate the need to purchase a stand-alone hair dryer, a real selling point in the current economy. Talking of the state of the world's finances, the beauty industry is one of the only markets not suffering amid the global economic downturn, with figures showing it is on track to exceed $990 billion ($US 646.20 billion) in revenue by 2025. In fact, Statista anticipates the beauty industry is expected to grow at an annual rate of 3.33 per cent from 2024 to 2028. It's believed the beauty and personal care market has thrived in the aftermath of the Covid-19 pandemic as consumers shifted to a greater focus on self-care and wellness. Additionally, changing consumer attitudes, particularly among younger generations, are driving demand for diverse and inclusive products that emphasise self-expression – and this is where Dyson's personalised offerings fit in. The brand also claims its multistyler is the only one on the market that includes this many attachments with purchase, arguing it makes the $999 price tag more palatable. Indeed, in the few hours since was first unveiled on social media, consumers have expressed eagerness to purchase the expensive item. 'Now this is a must!' one declared on Instagram within minutes, as another exclaimed: 'So excited to try it!!! Is it ready to order?' My 30 minute shocker Back in the airconditioned hotel room overlooking London's skyline, one of Dyson's pro hair stylists set to work showing me the Airwrap 2x in action, and I was surprised at just how quickly my hair took to finish. Within 30 minutes I went from having sweaty locks after hot footing it across the city in the 34 degree heat to a fresh wavy style. As I'm writing this, the curls are still very much in tact, an impressive feat – especially in humid weather. The product goes on sale in Australia on July 30 in two different colourways; Ceramic Pink and Jasper Plum.
News.com.au
17 hours ago
- News.com.au
OnlyFans' reclusive billionaire owner Leo Radvinsky in talks to sell site
The reclusive billionaire who built OnlyFans into one of the most lucrative and controversial subscription platforms on the internet is reportedly in talks with a buyer to sell his company for $US8 billion ($A12.2bn) — despite lingering concerns about pornographic content on the site. Leo Radvinsky, the sole owner of OnlyFans' London-based parent company Fenix International, was recently engaged in talks with an investor group led by the Forest Road Company, a Los Angeles-based investment firm, about a possible sale. But the status of those talks is unclear and it appears that Radvinsky has engaged another unnamed entity that is considered a more promising bidder, according to the Wall Street Journal. Last month, The Post reported that Radvinsky quietly put OnlyFans up for sale but that it was struggling to find a buyer due to its risque business model. News that Radvinsky is shopping OnlyFans comes after it was revealed that he collected nearly $US1.3 billion ($A2bn) in dividends between 2019 and early 2024, according to British corporate filings. Still, the mogul's ambition appears far from fulfilled. People familiar with the matter told the Journal that Radvinsky has recently engaged banks and suitors, sounding out a sale of OnlyFans for as much as $US8 billion. The Post has sought comment from Radvinsky, OnlyFans and Forest Road Company. While OnlyFans has become a cultural lightning rod and financial juggernaut — thanks largely to its explicit content and creator-led model — its owner remains almost entirely invisible. At 43, Radvinsky has never given a public interview, rarely appears at industry events and has left behind only a single widely circulated image online. Even those who've worked with him are bound by strict nondisclosure agreements. His official website describes him modestly as a company builder, an angel investor and an aspiring helicopter pilot. There's no mention of OnlyFans — despite the fact that the site is the primary source of his estimated $US4bn ($A6.1bn) fortune. A sale of OnlyFans at an $US8 billion valuation would further cement Radvinsky's place among the world's richest and most private tech entrepreneurs — and likely supercharge his philanthropic ambitions, according to the Journal. Despite its adult content roots, OnlyFans has tried to rebrand itself as a mainstream content platform. CEO Keily Blair, a former privacy lawyer, has stressed the site's diversity — highlighting comedy, sports, and music alongside more explicit fare. The price tag, while high, might actually be a bargain. OnlyFans is immensely profitable — something many fast-growing tech firms can't claim. But the very thing that makes it so lucrative could also be what keeps potential acquirers at bay. Even if a sale never materialises, Radvinsky doesn't seem pressed for cash. He and Chudnovsky relocated to Florida, where they now reside in a palatial duplex once owned by tennis great Chris Evert, purchased for over $20 million.
News.com.au
a day ago
- News.com.au
Health Check: And the EOFY biotech winner is … gasp … a pot stock
Bioxyne stars with a 720% gain in the 2024-25 year Paradigm shares soar 34% after $41 million convertible note deal Biotechs turn to debt funding The ASX biotech sector's best EOFY performer has come from left field: the local and European focused medicinal cannabis supplier Bioxyne (ASX:BXN). According to the Health Check Biotech Pulse – trademark pending – Bioxyne shares soared 720% in 2024-25, leaving its largely poorly performing pot peers in the dust. Bioxyne's fortunes have been driven by its Breathe Life Sciences arm, which purveys cannabis products including not just flowers and oils but pastilles, vapes, pessaries and suppositories (we kid you not). The company recently upgraded full-year revenue guidance from $25 to $28 million and promised positive cash flow and – gasp! – profitability. Amplia (ASX:ATX) took second place, with a 233% gain (300% over the last month). The stock soared after Amplia unveiled clinical trial results showing two 'complete responses' among a cohort of advanced pancreatic cancer patients. Orthocell (ASX:OCC) shares vaulted 220% on the back of US Food & Drug (FDA) approval of its novel nerve repair tool Remplir. Imricor Medical Systems (ASX:IMR) shares ended the year 189% to the good, as the company eyes FDA approval of its world's first MRI-guided ablation catheter. Other triple digit dazzlers were myelofibrosis drug developer Syntara (ASX:SNT) (up 130%), autism testing device play Blinklab (ASX:BB1) (up 116%) and the beloved radiology imaging tearaway ProMedicus (ASX:PME) (up 110%). Sorry – there's no prize for trying Sadly, there's still too much red ink in the rankings. In your columnist's opinion, investors have marked down many worthy stocks unfairly. But we're not in primary school and everyone doesn't get a ribbon for trying, so the record books will show that medication compliance group MedAdvisor (ASX:MDR) led the falls with an 82% decline. Other laggards are the multi-pronged Universal Biosensors (ASX:UBI) (down 76%), Proteomics International Laboratories (ASX:PIQ) (down 62%, see below), lung imager 4D Medical (ASX:4DX) (down 56%) and Clarity Pharmaceuticals (ASX:CU6) (down 51%). Shares in the busy Clarity shares peaked at $8.74 last October – a 70% gain for the year – but even after the subsequent sell off the company still bears an $800 million market cap. Strictly speaking, Opthea shares fared the worst after the company's infamous eye disease trail failure in March. Opthea shares never resumed trading, so the official records show a 73% gain when in fact the stock is worth next to nothing. Genetic Technologies and Nuheara are also missing from the laggards list, only because they went into administration and subsequently de-listed. Paradigm shifts to convertible notes With the equity capital raising outlook still looking shaky, Paradigm Biopharmaceuticals (ASX:PAR) has become the latest in a string of biotechs to tap alternative funding sources. The developer of a knee osteoarthritis (OA) drug candidate has tapped US$27 million ($41.2 million), by way of convertible notes. These have been issued to New York based alternative funder Obsidian Global Partners. Under the terms, Paradigm will draw an initial US$7 million to fund patient recruitment, trial operations and regulatory milestones. The balance of the facility is available at Paradigm's discretion, 'offering operational flexibility and strategic control over future funding needs'. Barring default, the notes are interest free. The cash will help to fund Paradigm's pivotal phase III trial of its repurposed drug candidate pentosan polysulphate sodium (PPS, or Zilosul). Investors have keenly awaited this trial initiation – and confirmation of how it will be funded. Reflecting this, Paradigm shares this morning surged 34%. The 466-patient study in underway across up to 15 Australian and 50 US sites. The company says it is now fully funded up to the interim analysis of the first 50% of patients, due in mid 2026. Last week Paradigm hedged its bets by paying as much as $16.5 million for Proteobioactives Pty Ltd ($500,000 upfront) This company owns an early-stage oral candidate for minor to mild OA, which combines PPS with a COX-2 inhibitor (Coxib). When debt is not a dirty word The term 'debt' can have unfortunate connotations – especially in the context of your columnist's household budget. But it can be cheaper than equity and has the benefit of being non-dilutive and more flexible with the timing of drawdowns. Often, it's simply more accessible than equity. The developer of better working anti-infectives, Recce Pharmaceuticals (ASX:RCE) last month availed of a US$20 million ($30 million) draw-down facility from the New York based Avenue Capital Group. Recce pockets an initial US$7.5 million and a further US$5 million between April and September this year. The remainder is available in calendar 2027, with all the amounts subject to 12.75% interest. The funds will support Recce's two phase III registrational studies on diabetic foot infections and acute bacterial skin and skin structure infections. Recce also recently raised $15.8 million of equity. Last month, dermatology group Botanix Pharmaceuticals (ASX:BOT) unveiled a circa US$30 million ($48 million) debt facility with Kreos Capital. Kreos is an arm of the world's biggest investment manager Blackrock. The facility provides for circa $US20 million to be drawn now, with the remainder to be tapped by October 2026 at the company's option. Under certain conditions, Kreos Capital can convert 20 percent of the loan into Botanix shares, at 33 cents apiece. Botanix developed Sofdra, a treatment for excessive underarm sweating and has started selling the product in the US. In mid-April Botanix also raised $40 million of equity, via an institutional placement. Proteomics secures non-dilutive $6 million Then there's non-dilutive grant funding. The Perth-based Proteomics today said it had secured a $6 million investment from the federally funded Bioplatforms Australia and the WA government. The funding will support developing an accredited protein biomarker analysis platform, in partnership with the University of Western Australia. Proteomics chips in $1 million over the three-year funding period. Proteomics has commercialised a predictive test for diabetic kidney disease and is developing assays for endometriosis, esophageal cancer and oxidative stress. Meso-blast off for FDA application? Stem-cell drug developer Mesoblast (ASX:MSB) says the company and the FDA are 'aligned' on what the company needs to do before it lodges a US marketing application for its heart disease candidate, Revascor. In late December Mesoblast won FDA approval for its childhood graft-versus-host disease (GvHD) candidate. This followed years of the company and the agency being decidedly 'unaligned'. Given the heart disease heart indication is much bigger than GvHD, today's news is more significant than it may appear at first blush. Mesoblast intends to file for accelerated approval by the end of the year. This is to treat ischemic heart failure patients with reduced ejection fraction and inflammation.
